Inovio’s proprietary platform is leading the way forward for activation immunotherapy. This one-of-a-kind platform delivers optimized DNA into cells, where it is translated into proteins that activate an individual’s immune system to generate a robust targeted T cell and antibody response. Inovio’s technology has generated impressive results in preclinical and clinical studies. VGX-3100, a product using the platform technology, has entered Phase 3 trials as the first immunotherapy for HPV-related cervical precancer.
http://ir.inovio.com/investors/stock-information/default.aspx
EbolaInfo 